Literature DB >> 18329613

Selective killing of nonreplicating mycobacteria.

Ruslana Bryk1, Benjamin Gold, Aditya Venugopal, Jasbir Singh, Raghu Samy, Krzysztof Pupek, Hua Cao, Carmen Popescu, Mark Gurney, Srinivas Hotha, Joseph Cherian, Kyu Rhee, Lan Ly, Paul J Converse, Sabine Ehrt, Omar Vandal, Xiuju Jiang, Jean Schneider, Gang Lin, Carl Nathan.   

Abstract

Antibiotics are typically more effective against replicating rather than nonreplicating bacteria. However, a major need in global health is to eradicate persistent or nonreplicating subpopulations of bacteria such as Mycobacterium tuberculosis (Mtb). Hence, identifying chemical inhibitors that selectively kill bacteria that are not replicating is of practical importance. To address this, we screened for inhibitors of dihydrolipoamide acyltransferase (DlaT), an enzyme required by Mtb to cause tuberculosis in guinea pigs and used by the bacterium to resist nitric oxide-derived reactive nitrogen intermediates, a stress encountered in the host. Chemical screening for inhibitors of Mtb DlaT identified select rhodanines as compounds that almost exclusively kill nonreplicating mycobacteria in synergy with products of host immunity, such as nitric oxide and hypoxia, and are effective on bacteria within macrophages, a cellular reservoir for latent Mtb. Compounds that kill nonreplicating pathogens in cooperation with host immunity could complement the conventional chemotherapy of infectious disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18329613      PMCID: PMC2423947          DOI: 10.1016/j.chom.2008.02.003

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  41 in total

Review 1.  Non-inherited antibiotic resistance.

Authors:  Bruce R Levin; Daniel E Rozen
Journal:  Nat Rev Microbiol       Date:  2006-07       Impact factor: 60.633

Review 2.  Novel approaches to developing new antibiotics for bacterial infections.

Authors:  A R M Coates; Y Hu
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

3.  A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.

Authors:  C K Stover; P Warrener; D R VanDevanter; D R Sherman; T M Arain; M H Langhorne; S W Anderson; J A Towell; Y Yuan; D N McMurray; B N Kreiswirth; C E Barry; W R Baker
Journal:  Nature       Date:  2000-06-22       Impact factor: 49.962

4.  Expression levels of Mycobacterium tuberculosis antigen-encoding genes versus production levels of antigen-specific T cells during stationary level lung infection in mice.

Authors:  Brian J Rogerson; Yu-Jin Jung; Ronald LaCourse; Lynn Ryan; Nicholas Enright; Robert J North
Journal:  Immunology       Date:  2006-06       Impact factor: 7.397

5.  In vitro activity of a new antibacterial rhodanine derivative against Staphylococcus epidermidis biofilms.

Authors:  Maxime Gualtieri; Lionel Bastide; Philippe Villain-Guillot; Sylvie Michaux-Charachon; Jaqueline Latouche; Jean-Paul Leonetti
Journal:  J Antimicrob Chemother       Date:  2006-07-30       Impact factor: 5.790

6.  Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis.

Authors:  Y Hu; A R Coates; D A Mitchison
Journal:  Int J Tuberc Lung Dis       Date:  2006-03       Impact factor: 2.373

7.  Peroxynitrite reductase activity of bacterial peroxiredoxins.

Authors:  R Bryk; P Griffin; C Nathan
Journal:  Nature       Date:  2000-09-14       Impact factor: 49.962

Review 8.  Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy.

Authors:  Digby F Warner; Valerie Mizrahi
Journal:  Clin Microbiol Rev       Date:  2006-07       Impact factor: 26.132

9.  Discovery of a rhodanine class of compounds as inhibitors of Plasmodium falciparum enoyl-acyl carrier protein reductase.

Authors:  Gyanendra Kumar; Prasanna Parasuraman; Shailendra Kumar Sharma; Tanushree Banerjee; Krishanpal Karmodiya; Namita Surolia; Avadhesha Surolia
Journal:  J Med Chem       Date:  2007-05-04       Impact factor: 7.446

10.  SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.

Authors:  Jay P Powers; Derek E Piper; Yang Li; Veronica Mayorga; John Anzola; James M Chen; Juan C Jaen; Gary Lee; Jinqian Liu; M Greg Peterson; George R Tonn; Qiuping Ye; Nigel P C Walker; Zhulun Wang
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

View more
  77 in total

1.  Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa.

Authors:  Veerle Liebens; Valerie Defraine; Wouter Knapen; Toon Swings; Serge Beullens; Romu Corbau; Arnaud Marchand; Patrick Chaltin; Maarten Fauvart; Jan Michiels
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  A journey in science: promise, purpose, privilege.

Authors:  Carl Nathan
Journal:  Mol Med       Date:  2013-10-03       Impact factor: 6.354

Review 3.  Enhancing the utility of existing antibiotics by targeting bacterial behaviour?

Authors:  Geraint B Rogers; Mary P Carroll; Kenneth D Bruce
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

4.  Art-175 is a highly efficient antibacterial against multidrug-resistant strains and persisters of Pseudomonas aeruginosa.

Authors:  Yves Briers; Maarten Walmagh; Barbara Grymonprez; Manfred Biebl; Jean-Paul Pirnay; Valerie Defraine; Jan Michiels; William Cenens; Abram Aertsen; Stefan Miller; Rob Lavigne
Journal:  Antimicrob Agents Chemother       Date:  2014-04-21       Impact factor: 5.191

Review 5.  The tuberculosis drug discovery and development pipeline and emerging drug targets.

Authors:  Khisimuzi Mdluli; Takushi Kaneko; Anna Upton
Journal:  Cold Spring Harb Perspect Med       Date:  2015-01-29       Impact factor: 6.915

6.  PUPylation provides the punch as Mycobacterium tuberculosis battles the host macrophage.

Authors:  Padmini Salgame
Journal:  Cell Host Microbe       Date:  2008-11-13       Impact factor: 21.023

7.  Studies of a ring-cleaving dioxygenase illuminate the role of cholesterol metabolism in the pathogenesis of Mycobacterium tuberculosis.

Authors:  Katherine C Yam; Igor D'Angelo; Rainer Kalscheuer; Haizhong Zhu; Jian-Xin Wang; Victor Snieckus; Lan H Ly; Paul J Converse; William R Jacobs; Natalie Strynadka; Lindsay D Eltis
Journal:  PLoS Pathog       Date:  2009-03-20       Impact factor: 6.823

8.  Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.

Authors:  Lucas R Hoffman; Anthony R Richardson; Laura S Houston; Hemantha D Kulasekara; Willm Martens-Habbena; Mikkel Klausen; Jane L Burns; David A Stahl; Daniel J Hassett; Ferric C Fang; Samuel I Miller
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

9.  A rhodanine agent active against non-replicating intracellular Mycobacterium avium subspecies paratuberculosis.

Authors:  Tim J Bull; Richard Linedale; Jason Hinds; John Hermon-Taylor
Journal:  Gut Pathog       Date:  2009-12-23       Impact factor: 4.181

10.  Mycobacterium avium subspecies paratuberculosis, Crohn's disease and the Doomsday scenario.

Authors:  John Hermon-Taylor
Journal:  Gut Pathog       Date:  2009-07-14       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.